Wednesday, December 20, 2006

Replidyne Completes Phase 2 Enrollment

Louisville, Colorado-based Replidyne said today that it has completed enrollment for a Phase 2 trial evaluating the firm's treatment for infections of the middle ear. The firm said that the study will include 300 children, and will be complete by the first quarter of 2007. Replidyne is commercializing faropenem medoxomil (faropenem), a treatment for pediatric patients with acute otitis media infections of the middle ear.